louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05172778: Observational Study of the Performance of Cephen Reagents in the Context of Research Into Lupus Anticoagulants
Official title: Observational Study of the Performance of Cephen Reagents in the Context of Research Into Lupus Anticoagulants
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lupus Anticoagulant
Keywords: Lupus Anticoagulant
Coagulation
Phospholipid
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-12-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject with blood sample already analyzed in the laboratory as part of the treatment by the reference method

Brief summary: Lupus anticoagulants (are antiphospholipid antibodies (PSA), the screening of which is done by demonstrating prolongation of coagulation times corrected by the intake of phospholipids (PL).

Learned societies (ISTH, CLSI) thus recommend, for the research of LA, to carry out initially two screening tests with a low concentration in PL: a time of diluted Russell viper venom (DRVVT) as well as a time activated partial thromboplastin (TCA). If one of these screening tests is positive, it is recommended to perform a second confirmation test using the same principle (DRVVT or TCA) and containing a higher concentration of PL.

The current LA screening method at the Hematology Laboratory of Strasbourg University Hospital includes: a pair of DRVVT screening / confirmation (STA-Staclot DRVV Screen and Confirm, Diagnostica Stago, France) and a screening TCA (PTT-A , Diagnostica Stago, France).

This study aims to compare with the current method of the investigators a pair of TCA screening / confirmation (Cephen LS / Cephen, Hyphen Biomed, France).


Eligibility criteria: Inclusion criteria:

* Major subject
* blood sample already analyzed in the laboratory as part of the treatment by the reference method
* Patient who did not express his opposition to the reuse of his data and his blood sample for the technical study.

Exclusion criteria:

* Minor patient
* Patient under curatorship, guardianship or legal protection
* Patient who expressed his opposition to the use of his data
* Insufficient sample

Primary outcomes:
measure: Observational study of the performance of Cephen reagents in the context of research into lupus anticoagulants
timeFrame: Files analysed retrospectively from January 01, 2019 to December 31, 2021 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Laboratoire d'Hématologie - Hôpitaux Universitaires de Strasbourg
Study officials:
affiliation: Laboratoire d'Hématologie - Hôpitaux Universitaires de Strasbourg
name: Agathe HERB, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03162471: How Astigmatism Influences Corneal Biomechanics and Intraocular Pressure
Official title: Impact of Preoperative Astigmatism on Corneal Biomechanics and Accurate Intraocular Pressure Measurement After Micro-incision Phacoemulsification
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corneal Astigmatism
Intraocular Pressure
Cataract Senile
Keywords: Corneal astigmatism
Cataract surgery
Corneal hysteresis
Corneal resistance factor
Intraocular pressure
Lead sponsor: Medical University of Lodz
Sponsor class: OTHER
First posted: 2017-05-22
Enrollment: 39
Sex: ALL
Minimum age (years): 52
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 39 patients diagnosed with cataracts were enrolled in the study

Brief summary: The aim of the study was to identify whether preoperative corneal astigmatism can influence corneal biomechanics and the assessment of intraocular pressure (IOP) following micro-incision phacoemulsification.


Eligibility criteria: Inclusion Criteria:

* diagnosis and qualification for cataract surgery, corneal astigmatism of equal to or less than 2.25 Dcyl

Exclusion Criteria:

* corneal astigmatism higher than 2.25 Dcyl, history of any other corneal disease (infection, trauma, ulceration, autoimmune inflammation, Fuchs Dystrophy, keratoconus, corneal scars, preoperative insufficiency of corneal endothelium), glaucoma and chronic use of non-glaucoma eye drops, blepharitis, dry eye, use of contact lenses diabetes or a history of corneal refractive surgery

Primary outcomes:
measure: change of corneal compensated IOP (IOPcc)
timeFrame: Parameter measured preoperatively and one day, one week, one month postoperatively
Secondary outcomes:
measure: change of corneal hysteresis (CH)
timeFrame: Parameter measured preoperatively and one day, one week, one month postoperatively
measure: change of corneal resistance factor (CRF)
timeFrame: Parameter measured preoperatively and one day, one week, one month postoperatively
measure: change of Goldman-correlated IOP (IOPg)
timeFrame: Parameter measured preoperatively and one day, one week, one month postoperatively
measure: change of waveform score (WS)
timeFrame: Parameter measured preoperatively and one day, one week, one month postoperatively
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00544271: Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.
Official title: Phase IIIb Study to Evaluate Immunogenicity, Antibody Persistency and Reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX Vaccines Administered to Healthy Children Previously Primed With 3 Doses of DTPa Vaccine Compared to Placebo (HAVRIX®JUNIOR)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Acellular Pertussis
Tetanus
Diphtheria
Keywords: BOOSTRIX
INFANRIX
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-10-16
Enrollment: 720
Sex: ALL
Minimum age (years): 18
Maximum age (years): 20
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate the immunogenicity, persistence of antibodies and reactogenicity of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX), when administered to subjects 18-20 months old, compared with not giving a booster DTP vaccine at 18-20 months. Study double blinded for the two DTP vaccines and single blinded for the control arm.


Eligibility criteria: Inclusion Criteria:

* Male or female children between and including 18 -20 months of age at the time of the vaccination.
* Completed a primary vaccination course with DTPa (INFANRIX) vaccine at 2, 4, and 6 months.
* Written informed consent obtained before study entry from the parents or guardians of the subject.
* Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the administration of the study vaccine dose, or planned use during the study period.
* Evidence of previous or intercurrent diphtheria, tetanus, or pertussis disease, or of vaccination against any of these diseases since completion of the primary course of DTPa (INFANRIX) vaccine.

Primary outcomes:
measure: Anti-diphtheria and anti-tetanus antibody concentration (1M, 15-18M & 27-29M after vacc)
measure: Occurrence of local injection site reactions (1M after vacc).
Secondary outcomes:
measure: Antibody concentration to all vaccine antigens (1M, 15-18M & 27-29M after vacc),
measure: Solicited (Day 0-14) & Unsolicited symptoms (Day 0-30),
measure: SAEs (full study).
Other outcomes:
Locations:
city: Carlton
country: Australia
facility: GSK Investigational Site
state: Victoria
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00043771: Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Official title: Multi-Center, Double-Blind Study to Compare the Effects of 30mg Qd Versus 15 Mg Bid of Tolvaptan in Congestive Heart Failure Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Congestive Heart Failure
Keywords: CHF
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
First posted: 2002-08-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.


Eligibility criteria: History of CHF

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bakersfield
country: United States
facility: Central Cardiology Medical Clinic
state: California
city: San Diego
country: United States
facility: University of California-San Diego
state: California
city: Miami
country: United States
facility: University of Miami/Jackson Memorial Hospital
state: Florida
city: Slidell
country: United States
facility: Medical Research Institute
state: Louisiana
city: Auburn
country: United States
facility: Androscoggin Cardiology Associates
state: Maine
city: Kansas City
country: United States
facility: University of Missouri-Kansas City School of Medicine
state: Missouri
city: St. Louis
country: United States
facility: Saint Louis University
state: Missouri
city: Tulsa
country: United States
facility: Cardiology of Oklahoma
state: Oklahoma
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
References:
Clinical trial NCT06906471: A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Official title: A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Prostate Cancer
Prostate Cancer (Adenocarcinoma)
Fluorescence Imaging
Keywords: fluorescent agent
PSMA
prostate surface membrane antigen
histopathology
fluorescence-guided surgery
Lead sponsor: Antelope Surgical Solutions, Inc
Sponsor class: INDUSTRY
First posted: 2025-04-02
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS


Eligibility criteria: Inclusion Criteria:

* suspected prostate cancer warranting standard of care multi-core prostate biopsy

Exclusion Criteria:

* Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
* Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature
* Patients with a creatinine clearance cutoﬀ (CrCl) of \< 60 mL/min

Primary outcomes:
measure: Safety of AS1986NS
timeFrame: Enrollment to 30 days post single infusion
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Icahn School of Medicine at Mount Sinai (ISMMS)
state: New York
city: Taoyuan City
country: Taiwan
facility: Linkou Chang Gung Memorial Hospital
Study officials:
References:
citation: Kommidi H, Guo H, Nurili F, Vedvyas Y, Jin MM, McClure TD, Ehdaie B, Sayman HB, Akin O, Aras O, Ting R. 18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management. J Med Chem. 2018 May 10;61(9):4256-4262. doi: 10.1021/acs.jmedchem.8b00240. Epub 2018 Apr 20.
citation: Guo H, Kommidi H, Vedvyas Y, McCloskey JE, Zhang W, Chen N, Nurili F, Wu AP, Sayman HB, Akin O, Rodriguez EA, Aras O, Jin MM, Ting R. A Fluorescent, [18F]-Positron-Emitting Agent for Imaging Prostate-Specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells. ACS Chem Biol. 2019 Jul 19;14(7):1449-1459. doi: 10.1021/acschembio.9b00160. Epub 2019 Jun 17.
citation: Aras O, Demirdag C, Kommidi H, Guo H, Pavlova I, Aygun A, Karayel E, Pehlivanoglu H, Yeyin N, Kyprianou N, Chen N, Harmsen S, Sonmezoglu K, Lundon DJ, Oklu R, Ting R, Tewari A, Akin O, Sayman HB. Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study. Clin Genitourin Cancer. 2021 Oct;19(5):405-416. doi: 10.1016/j.clgc.2021.03.011. Epub 2021 Mar 19.
Clinical trial NCT01046071: The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy
Official title: The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Laparoscopic Cholecystectomy
Keywords: Transversus abdominis plane block, postoperative pain.
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
First posted: 2010-01-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Transversus abdominis plane block as part of a multimodal postoperative regimen is superior to control in analgesic efficacy after laparoscopic cholecystectomy.


Eligibility criteria: Inclusion Criteria:

* Laparoscopic cholecystectomy
* ASA 1-3
* BMI 18-35
* Written consent

Exclusion Criteria:

* Do not understand danish
* Drug allergy
* Pregnancy
* Alcohol or drug abuse
* Chronic pain with consumption of opioids
* Consumption of NSAID, COX2inhibitors or paracetamol within 24 hours before the investigation
* Infection at the needle site.

Primary outcomes:
measure: Pain during cough.
timeFrame: 0,2,4,6,8,24 hours postoperative
Secondary outcomes:
measure: Pain during rest
timeFrame: 0,2,4,6,8,24 hours postoperative
measure: Total opioid consumption
timeFrame: 0-24 hours postoperative
measure: Postoperative nausea and vomiting
timeFrame: 0,2,4,6,8,24 hours postoperative
measure: Sedation
timeFrame: 0,2,4,6,8,24 hours postoperative
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Glostrup University Hospital, Department of anesthesia
Study officials:
affiliation: Copenhagen University Hospital, Glostrup
name: Pernille L Petersen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01329471: Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myeloid Leukemia
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: Weizmann Institute of Science
First posted: 2011-04-06
Enrollment: 75
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Female hospital patients

Brief summary: The purpose of this study is to elucidate the role of RUNX1 in Acute Myeloid Leukemia (AML), in particular, the transcriptional regulation of genes by mutated forms of this protein. This research will study the effect of mutations found in AML patients

Detailed description: The RUNX1 gene, located at chromosomal band 21q22, is a transcription factor, crucial for hematopoiesis and the generation of hematopoietic stem cells in the embryo. RUNX1 is the most frequent target for chromosomal translocation in leukemia. In addition, point mutations in the RUNX1 gene have been found to constitute an important mode of genetic alteration in development of leukemia. Recent publications stressing the clinical need for implementing RUNX1 point mutations as both a diagnostic and unfavorable prognostic marker of AML, have aroused particular interest in the functional role of RUNX1 in this disease.

In order to pinpoint specific RUNX1 target genes involved in pre-leukemic transformation or exacerbation of existing leukemia, the investigators plan to compare expression profiles from human hematopoietic progenitors overexpressing a mutated form of RUNX1with controls (RUNX1 wild-type and knocked-down). In this study the investigators intend to collect blood, after receiving informed consent, from umbilical cords of neonates born vaginally, in order to isolate CD34+ hematopoietic progenitors. Human umbilical cord blood contains relatively high numbers of CD34+ cells, which may be frozen directly after collection and used as a source of progenitor cells for further culture or direct analysis.

Eligibility criteria: Inclusion Criteria:

* Consenting women who have had full-term birth

Exclusion Criteria:

* Systemic disease

Primary outcomes:
measure: Performance of expression arrays on transfected CD34+ cells
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT02651571: Survival Rates of Patients With Mobile Bearing Total Knee Arthroplasty After 10 Years
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Knee Replacement
Keywords: Knee
Replacement
Prosthesis
Mobile-bearing
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2016-01-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients wearing total knee prosthesis with mobile plate for over 10 years

Brief summary: The total knee replacement has become a routine procedure. Survival rate of over 90% after 10 years are generally reported. However, complications and reoperation may still occur for many reasons, and some of them may be related to component design: loosening (tibial above), polyethylene wear, knee stiffness, ligamentous instability, etc ... . Therefore, new designs can, at least in theory, improve the results of conventional models.

In this study, the investigators want to compare retrospectively data concerning survival rates of patients wearing total knee prosthesis with mobile plate for over 10 years, with the ones published in the literature for conventional fixed-bearing prostheses.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years
* Patients wearing total knee prosthesis with mobile plate for over 10 years

Exclusion Criteria:

* Patients under 18 years

Primary outcomes:
measure: Compare retrospectively data concerning survival rates of patients wearing total knee prosthesis with mobile plate for over 10 years, with the ones published in the literature for conventional fixed-bearing prostheses.
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Jean-Yves JENNY, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01498471: NICE Guideline 'Red Flags' to Predict Serious Outcome After Transient Loss of Consciousness
Official title: NICE Guideline 'Red Flags' to Predict Serious Outcome After Transient Loss of Consciousness: Prospective Validation Study in the Emergency Department.
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Syncope
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2011-12-23
Enrollment: 0
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients (\>= 16 years) presenting in the ED with a complaint of TLoC

Brief summary: This study is designed to evaluate the accuracy of the National Institute for Health and Clinical Excellence (NICE) guideline 'red flags' to identify patients at high risk of short term serious outcome when presenting in the emergency department (ED) with Transient Loss of Consciousness (TLoC). Red flags were defined as ECG abnormality, history or physical signs of heart failure, TLoC during exercise, family history of sudden cardiac death at an age \< 40 years and/or an inherited cardiac condition, new or unexplained breathlessness, heart murmur, absence of prodromal symptoms in any patient aged \> 65 years.


Eligibility criteria: Inclusion Criteria:

* Adult patients (\>= 16 years) with a complaint of TLoC

Exclusion Criteria:

* Patients needing immediate treatment, with trauma related or drug or alcohol related TLoC were excluded, as well as patient with persistent altered level of consciousness, simple fall and drop attack

Primary outcomes:
measure: serious outcome
timeFrame: day 7
Secondary outcomes:
measure: serious outcome
timeFrame: 1 year
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospitals Leuven
Study officials:
References:
Clinical trial NCT01679171: One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically Ventilated
Official title: One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically Ventilated
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Elderly Care
Keywords: Elderly
Intensive care unit
Outcome
Comprehensive geriatric assessment
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2012-09-05
Enrollment: 489
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients aged 75 and over admitted in one of the participating ICU and requiring mechanical ventilation will be recruited for this study

Brief summary: Elderly patients are increasingly admitted in the Intensive Care Unit. Short-term outcome (e.g. hospital survival) of an ICU stay is improving in this population but little data have been published on long-term outcome. Beyond survival, outcome assessment in the elderly requires to evaluate several aspects of health: mental status, activity of daily living, pain, depression, frailty... referred by geriatrician as "comprehensive geriatric assessment' (CGA).

The purpose of the SENIOREA study is to evaluate one year outcome of elderly patients mechanically ventilated in the ICU by performing CGA one year after ICU admission. CGA will be performed on the patients' site of living.

This prospective multicentric trial will be conducted over 8 medico-surgical ICUs.


Eligibility criteria: Inclusion Criteria:

1. Patients aged 75 or over
2. Admitted in a participating ICU
3. Requiring mechanical ventilation (invasive or non invasive), initiated before ICU admission or during the 48 first hours after admission.

Exclusion Criteria:

1. Non French-speaking person
2. Failure to obtain a consent by persons authorized to do so.
3. Person non-beneficiary of a social security system.

Primary outcomes:
measure: One year outcome
timeFrame: 1 year
Secondary outcomes:
measure: Predictors of one-year outcome
timeFrame: one year
Other outcomes:
Locations:
city: Angers
country: France
facility: Intensive care unit - CHU Angers
Study officials:
affiliation: CHU Angers France
name: Nicolas Lerolle
role: PRINCIPAL_INVESTIGATOR
References:
citation: Demiselle J, Duval G, Hamel JF, Renault A, Bodet-Contentin L, Martin-Lefevre L, Vivier D, Villers D, Lefevre M, Robert R, Markowicz P, Lavoue S, Courte A, Lebas E, Chevalier S, Annweiler C, Lerolle N. Determinants of hospital and one-year mortality among older patients admitted to intensive care units: results from the multicentric SENIOREA cohort. Ann Intensive Care. 2021 Feb 17;11(1):35. doi: 10.1186/s13613-021-00804-w.